Chartwell Investment Partners LLC Decreases Position in Aerie Pharmaceuticals Inc (AERI)

Chartwell Investment Partners LLC reduced its stake in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 5.6% in the 4th quarter, HoldingsChannel.com reports. The firm owned 24,158 shares of the company’s stock after selling 1,433 shares during the quarter. Chartwell Investment Partners LLC’s holdings in Aerie Pharmaceuticals were worth $1,443,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of AERI. Vanguard Group Inc. boosted its holdings in shares of Aerie Pharmaceuticals by 55.0% during the second quarter. Vanguard Group Inc. now owns 2,158,825 shares of the company’s stock worth $113,446,000 after purchasing an additional 766,300 shares during the period. Russell Investments Group Ltd. boosted its holdings in shares of Aerie Pharmaceuticals by 67.1% during the third quarter. Russell Investments Group Ltd. now owns 388,666 shares of the company’s stock worth $18,889,000 after purchasing an additional 156,056 shares during the period. Columbus Circle Investors boosted its holdings in shares of Aerie Pharmaceuticals by 41.0% during the third quarter. Columbus Circle Investors now owns 519,806 shares of the company’s stock worth $25,263,000 after purchasing an additional 151,133 shares during the period. Suffolk Capital Management LLC boosted its holdings in shares of Aerie Pharmaceuticals by 94.4% during the third quarter. Suffolk Capital Management LLC now owns 283,507 shares of the company’s stock worth $13,778,000 after purchasing an additional 137,654 shares during the period. Finally, Alyeska Investment Group L.P. boosted its holdings in shares of Aerie Pharmaceuticals by 218.8% during the third quarter. Alyeska Investment Group L.P. now owns 191,282 shares of the company’s stock worth $9,296,000 after purchasing an additional 131,282 shares during the period. Institutional investors and hedge funds own 99.02% of the company’s stock.

Shares of Aerie Pharmaceuticals Inc (AERI) opened at $54.20 on Wednesday. The company has a debt-to-equity ratio of 0.78, a current ratio of 15.24 and a quick ratio of 15.24. Aerie Pharmaceuticals Inc has a one year low of $38.14 and a one year high of $66.60.

Several research firms recently commented on AERI. BidaskClub upgraded shares of Aerie Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, December 5th. Zacks Investment Research cut shares of Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. HC Wainwright started coverage on shares of Aerie Pharmaceuticals in a research note on Friday, February 16th. They issued a “buy” rating and a $78.00 target price for the company. Canaccord Genuity set a $73.00 target price on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, November 16th. Finally, Mizuho reiterated a “buy” rating and issued a $87.00 target price on shares of Aerie Pharmaceuticals in a research note on Tuesday, December 19th. Four equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $74.21.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/02/21/chartwell-investment-partners-llc-decreases-position-in-aerie-pharmaceuticals-inc-aeri.html.

Aerie Pharmaceuticals Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals Inc (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply